| Metacrine is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with gastrointestinal, or GI, diseases. Co.'s program, MET642, targets the farnesoid X receptor, or FXR, which is central to modulating GI and liver diseases. Co. is developing another FXR agonist, MET409, for the treatment of non-alcoholic steatohepatitis, or NASH, a liver disease characterized by excess liver fat, inflammation and fibrosis. Co. is also developing small molecule inhibitors of hydroxysteroid dehydrogenase 17b13, or HSD17ß13, for the treatment of NASH. HSD17ß13 is a genetically validated target for liver disease. We show 10 historical shares outstanding datapoints in our MTCR shares outstanding history coverage, used to compute MTCR market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing MTCR market cap history over the course of time is important for investors
interested in comparing MTCR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of MTCR versus a peer is one thing; comparing
MTCR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like MTCR can fluctuate over the course of history.
With this page we aim to empower investors researching MTCR by allowing them to research the MTCR market cap history.